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Abstract  
 
Background: Whereas the role of externalizing disorders is relatively well established in predicting the 
onset of cannabis use (CU) or cannabis use disorder (CUD), the status of anxiety and mood disorders 
in predicting CU and CUD remains controversial.  
Objective: (1) To examine cross-sectional and prospective associations of CU and CUD with a range 
of mental disorders and whether anxiety and mood disorders are associated with CU/CUD after 
adjusting for externalizing disorders.  
Methods: N = 1395 community subjects aged 14–17 at baseline were followed-up at three waves 
prospectively over 10 years. Substance use, substance disorders and mental disorders were assessed 
using the DSM-IV/M-CIDI.  
Results: (1) The baseline prevalence rates where 19.3% at t0 for CU and 2.6% for CUD. Cumulative 
incidence rates at t3 were 54.3% for CU and 13.7% for CUD. (2) In cross-sectional and prospective 
analyses other substance use disorders, mood and anxiety disorders were associated with CU and 
CUD. (3) Associations of panic-anxiety with CU and of depressive and bipolar disorders with CU and 
CUD were significant after controlling for externalizing disorders.  
Conclusion: A range of psychopathological conditions, including depressive, bipolar and less 
consistently anxiety disorders as well as the degree of their comorbidity are significantly associated 
with incident CU and progression to CUD, even when controlling for externalising disorders. A better 
understanding of this complex interplay may result in better aetiological models and intervention 
strategies.   
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1. Introduction  
 
A substantial number of studies have examined the relationship of mental disorders and illicit 
substance use and substance use disorders including cannabis. We identified six general 
population or community studies in adolescents (up to 18 years of age) with a prospective-
longitudinal design and standardized assessment of disorders according to DSM-IV or ICD-10 
criteria that also provide data on the association of cannabis use (CU)/cannabis use disorder 
(CUD) and mental disorders (Table 1).  
 
The studies, however, differ considerably with regard to the coverage of diagnoses and 
respectively the assessment of mental disorders and syndromes, sampling, age of inclusion, 
length and frequency of follow-up, as well as many technical aspects of analyses, such as 
control for confounders. Possibly as the result of this methodological variation, there is also 
some variation in findings. In particular two issues remain unclear: (a) the role of anxiety and 
depressive (so-called internalizing disorders) for onset of CU and CUDs, (b) the role of 
specific disorders (such as bipolar disorders, panic disorder, social phobia, etc.), and (c) 
whether anxiety and depressive disorders play a role beyond the well documented effect of 
externalizing disorders such as conduct, anti-social personality disorder (ASP) and attention-
deficit/hyperactivity disorder (ADHD).  
 
McGee et al. (2000) reported from the Dunedin Multidisciplinary Health and Development 
Study only associations of any mental disorder and CU. The other epidemiological 
prospective studies focused on specific disorders or major diagnostic subgroups; of these, five 
studies reported associations with externalizing disorders, and five with depressive and 
anxiety disorders. All studies that focused on externalising disorders reported consistently 
strong associations of conduct disorder on CU or CUD (Boyle et al., 1992; King et al., 2004; 
Fergusson et al., 2007; Pedersen et al., 2001; Sung et al., 2004). Boyle et al. (1992) found no 
association to ADHD, and King et al. (2004), in a study on twins, found only weak 
associations. Fergusson et al. (2007) reported that the association of ADHD and substance use 
disorders was mediated by conduct problems. Findings on depressive disorders are 
inconsistent. Overall, only weak associations are found for depressive disorders and none of 
these studies identified associations to hypomania/mania. Fergusson et al. (2002) found that 
major depression was associated with CU in the Christchurch Health and Development Study 
across all age groups. Boyle et al. (1992) as well found no association with depressive 
disorders, and King et al. (2004) reported only weak effects. In the Children in the 
Community Study (Brook et al., 2002) an opposite association was found, as cannabis and 
other illicit drug use predicted major depression. Even less attention is paid so far to the 
association of CU and anxiety disorders. In the Christchurch Health and Development Study 
(Goodwin et al., 2004) anxiety as a major diagnostic subgroup was significantly associated 
with substance dependence (OR: 1.3–3.9); however, after adjustment for childhood and 
family factors, prior substance dependence, co-morbid depression and peer affiliations, 
associations between anxiety and substance dependence disappeared. Associations for 
specific anxiety disorders remained unclear, due to low statistical power and the observation 
that the influence of other third variables might actually account for some or all of the 
association (Fig. 1).  
 
In contrast, within the Munich Early Developmental Stages of Psychopathology (EDSP) 
Study various publications have highlighted significant association of substance use (SU) and 
substance use disorders (SUD) and specific anxiety and depressive disorders. For example, 
ecstasy use was associated with increased risk for almost all mental disorders examined (Lieb 
et al., 2002); the onset of mental disorders occurred prior to the first use of ecstasy in the vast 
majority of these cases. One to two year follow-up data suggested that 22% of regular CUDs 
had pre-existing anxiety disorders and 37% pre-existing affective disorders (Höfler et al., 
1999). Wittchen et al. (2004) highlighted the increased rates of anxiety and/or depressive or 
childhood disorder among EDSP respondents reporting CU during adolescence or young 
adulthood using 4-year follow-up data and suggested that anxiety and mood disorders among 
CU subjects might increase the probability of progression to more severe substance use 
disorders. However, using the same data set, anxiety disorders were not confirmed to 
significantly predict progression from CU to cannabis use disorders in the 4-year follow-up 
(von Sydow et al., 2002a). Other noteworthy findings from their study also highlighted the 
potential critical role of CU in adolescence as a promoter for other psychopathology. For 
example, Henquet et al. (2005) found that CU increased the risk of psychotic symptoms 
especially among those with a pre-existing liability for psychosis (Henquet et al., 2005).  
 
To summarize, few prospective-longitudinal community studies have simultaneously 
examined the role of various mental disorders for using cannabis and other illicit drugs, and 
for developing substance use disorders through adolescence and early adulthood. Based on 
cross-sectional and longitudinal evidence various types of externalizing disorders seem to be 
well established as risk factors at least for initiation of CU and the use of other substances. 
The role and the implications of specific anxiety, mood and other internalizing disorders in 
predicting cannabis and other illicit drug use disorders, however, remains controversial.  
 
This leads to the specific objectives of this paper: (1) Because this is the first publication that 
includes the 10-year follow-up data we first present baseline and 10-year cumulative 
incidence rates of substance use and substance use disorders in adolescents aged 14–17 years 
at the outset of the study. (2) Focusing on cannabis as the most frequent illegal drug of abuse 
in this sample, we then examine cross-sectional and prospective associations of cannabis use 
and cannabis use disorders with a wide range of mental disorders. (3) Last, we examine 
whether anxiety and depressive disorders predict onset of CU and CUD beyond the effects of 
conduct and other externalizing disorders.  
 
2. Methods  
 
2.1. Sample and overall design  
 
Data were collected as part of the Early Developmental Stages of Psychopathology (EDSP) 
study. Objective, sample and design have already been reported elsewhere (Lieb et al., 2000; 
Wittchen et al., 1998a,b). Briefly, the EDSP is designed to explore prevalence and incidence, 
familial and other risk factors, co-morbidity and course of substance use and substance use 
disorders in a representative population sample of adolescents and young adults over a 10- 
year period with three follow-up examinations. The baseline sample was drawn in 1994 from 
government registries in metropolitan Munich, Germany. For the purpose of this paper only 
data from the four youngest age cohorts (N= 1395), namely ages 14–17 at baseline will be 
considered.  
 
The baseline survey was conducted in 1995 (T0, N= 1395, response rate 74.6%); the follow-
up examinations took place approximately 1.5 (t1), 4 (t2) and 10 (t3) years later. Response 
rates at t1 for the sample considered for this publication were 88.0% (N= 1228), 83.8% at t2 
(N= 1169) and 73.0% at t3 (N= 1019). At the final wave the age range of subjects was 21–27. 
It should be noted that (n = 85) participants who denied the mandatory commitment probes to 
answer questions on illicit drug use and disorders truthfully and openly at one or more waves, 
were excluded from the analyses referring to illicit substances resulting in N= 1324 subject 
participants at baseline, and N= 1310 in the longitudinal sample with last case carried forward 
analyses.  
 
2.2. Diagnostic assessment  
 
Participants were interviewed at each wave with the baseline and respective follow-up 
versions of the Munich-Composite International Diagnostic Interview (DIA-X/M-CIDI) 
(Wittchen et al., 1995; Wittchen and Pfister, 1997), an updated version of the World Health 
Organization (WHO) CIDI (Wittchen and Semler, 1991). The DIA-X/M-CIDI allows for the 
assessment of symptoms, syndromes, and diagnosis of 48 mental disorders, along with 
information about onset, duration, severity, and psychosocial impairment. The diagnosis of 
mental disorders presented in this article is based on the M-CIDI/DSM-IV algorithms. The 
DIA-X/M-CIDI is supplemented by a separate respondents’ booklet that includes disorder-
specific questionnaires as well as symptom lists and cognitive aids to assist the respondent in 
dating symptom onset and recency, answering complicated symptom questions, and 
identifying course patterns. Test–retest reliability and validity for the full DIA-X/M-CIDI 
have been reported elsewhere (Reed et al., 1998; Wittchen, 1994; Wittchen et al., 1998a,b), 
along with descriptions of the DIA-X/M-CIDI format and coding conventions. A total of 32 
clinical interviewers conducted the M-CIDI-interviews. All interviewers, most of whom were 
clinical psychologists, received an intensive 1-week training on the M-CIDI, followed by at 
least 10 closely monitored practice interviews.  
 
2.2.1. Assessment of substance use and substance use disorders.  
Use of nicotine, alcohol and drugs, including cannabis, were assessed with the M-CIDI 
substance use modules as well as abuse, and dependence according to DSM-IV. Details have 
been presented in Lachner et al. (1998), as well as von Sydow et al. (2001, 2002a,b), and 
Zimmermann et al. (2005). The substance use sections start with an extensive quantity-
frequency screen for use of the substances followed by questions on frequency and quantity 
for the respective reference periods (current, time period between interviews and lifetime), as 
well as symptoms of abuse and dependence. All sections close with questions on onset, 
duration, and recency of use and symptoms. In the drug section a list containing specific 
substances together with their “street-names” is presented probing for eight classes: cannabis, 
stimulants/amphetamines, opioids, cocaine, PCP, hallucinogens, inhalants as well as 
sedatives/hypnotics/anxiolytics. An open category of any other substance and a category of 
polysubstance use were added. Questions on symptoms of DSM-IV abuse and dependence of 
illicit substances were only applied to those who had used these substances more than four 
times. Among participants unwilling to respond to illicit drug use openly (‘commitment 
probe’), the section was not administered. Test–retest reliability of these sections ranges 
between a κ of 0.55 for drug abuse and a κ of 0.64 for nicotine dependence. Good agreement 
was found for the quantity and frequency questions. In case of validity there was a good 
agreement between DSM-IV diagnoses for substance use disorders assigned by clinicians and 
those assessed with the M-CIDI and assigned according to the M-CIDI DSM-IV algorithms 
(κ = 0.86).  
 
2.2.2. Assessment of mental disorders.  
Mental disorders were assessed with the M-CIDI at baseline and follow-ups using DSM-IV 
criteria, covering mood disorders (major depression, dysthymia, hypomania and 
mania/bipolar I or bipolar II), anxiety disorders (panic disorder, generalized anxiety disorder 
(GAD), agoraphobia, social phobia, specific phobia, separation anxiety disorder, obsessive-
compulsive disorder (OCD), post-traumatic stress disorder (PTSD), somatoform disorders 
(pain disorder and somatization), and eating disorders. From a wide range of childhood 
disorders (conduct problems, ADHD, ODD (oppositional-defiant disorder)) and other 
childhood conditions (e.g. tics, enuresis and encopresis, sleep disorder), the externalizing 
disorders (conduct problems, ODD, ADHD)were used for the predictor analysis. Conduct 
problems were defined dimensionally with one symptom (low), two symptoms (middle), and 
three or more symptoms (high) out of 23 questions. Separation anxiety was assessed at first 
follow-up according to DSM-IV.  
 
In the analyses “any mental disorder” was defined as having any mood disorder, any anxiety 
disorder (like defined above), any somatoform disorder, any substance use disorder (without 
cannabis and without all illicit substances) as well as childhood disorders. Panic-attacks and 
panic-disorder were aggregated into the variable panic-anxiety, to increase statistical power.  
 
2.3. Statistical analysis  
 
Data were weighted to account for different sampling probabilities (14 and 15 years olds were 
sampled with a higher probability) as well as systematic nonresponse at baseline (Lieb et al., 
2000). The Stata Software package (StataCorp., 2003) was used to calculate proportions and 
standard errors as well as robust confidence intervals required when analyses are based on 
weighted data (Royall, 1986).  
 
Cumulative lifetime incidences were generated using the last observation carried forward 
(LOCF) method, which means for each individual, missing values are replaced by the last 
observed value for each variable. Logistic regression models (Agresti, 1990; Long and Freese, 
2003) were used to examine associations between mental disorders and CU/CUD. Prospective 
associations were calculated between baseline mental disorders and cumulative lifetime 
incidence rates for CU and CUD up to t3. All regressions were controlled for gender. The 
estimated coefficients were transformed to odds ratios (ORs). Odds ratios describe the change 
in the chance of appearance of a particular outcome relative to the comparison group per unit 
increase in the covariate.  
 
Furthermore, survival analyses were conducted in order to use the full information of onset of 
CU and CUDs, respectively, and prior mental disorders until T0, T1, T2, T3, taking into 
account the ages of onset as well as age censoring at T0, T1, T2 or T3. Cox regressions with 
time dependent covariates were fitted (Therneau and Grambsch, 2000) stratified for gender 
and age cohort. Minor numbers of missing values of age of onset data (<10%) were replaced 
with the median in the respective age group (four different age groups were used). The 
Kaplan–Meier estimator was used to graph the age dependent cumulative lifetime incidence. 
Differences between cases, for example with and without a prior anxiety disorder were 
quantified with hazard ratios, that is, the factor by which cases and non-cases differ in the risk 
for the subsequent outcome. The proportional hazards assumption was tested using 
Schoenfeld residuals (Grambsch and Therneau, 1994).  
 
3. Results  
 
3.1. Prevalence and cumulative incidence of substance use and substance use disorders  
 
Table 2 presents the baseline prevalence (t0) and 10 years follow-up (t3) cumulative incidence 
of substance use (SU) and substance use disorders (SUD; abuse and dependence) of alcohol, 
nicotine, cannabis, and other illicit substances by baseline age group.  
 
3.1.1. Baseline findings for SU.  
About 90.5% of all adolescents reported having ever used any substance, most frequently 
alcohol (85.7%) and nicotine (68.6%), less frequently cannabis (19.3%) and other illicit drugs 
(4.8%). Use rates increase by age cohort, with 14 years old having the lowest use rates and 17 
years old the highest. For CU, rates were 5.4% among 14 years old, 20.8% in 15 years old, 
23.8% at age 16 and 29.2% at age 17. Except for illicit drugs, differences by age group seem 
to be less pronounced between ages 16 and 17. For cannabis use, increase in cumulative use 
rates was strongest between ages 14 (5.4%) and 15 (20.8%). For alcohol use (67.7–86.3%) 
and nicotine use (56.2–71.2%), increases between ages 14 and 15 were less pronounced.  
 
3.1.2. Baseline findings for SUD.  
At baseline rates were 12.5% for nicotine, 7.4% for alcohol and 2.6% for CUD. Rates for 
alcohol, nicotine and other illicit substance disorders differed slightly between age groups, 
with slightly higher rates in each successive age cohort considered. Increase of SUD of other 
illicit substances was strong between age cohort 16 and 17. For CUD, a pronounced increase 
was found between age groups 14 (0.6%) and 15 (3.2%), while rates remained relatively 
stable from age groups 15 to 16 (3.1%) and 17 (3.9%).  
 
3.1.3. Cumulative incidence at t3.  
Rates (across all age groups) for use as well as for use disorders increase from baseline to 
final follow-up 10 years later. Cumulative incidence rates for use increased to values of 
95.1% for alcohol and of 54.3% for cannabis. Rates for use disorders increased to a high of 
28.2% for nicotine, to 27.8% for alcohol and to 13.7% for CUD. The increase in rates for CU 
(19.3% prevalence at t0 and 54.3% cumulative incidence at t3) and use of other illicit 
substances (4.8% at t0 and 19.7% at t3) was especially pronounced, the differences for 
alcohol (85.7% at t0 and 95.1% at t3) and nicotine use (68.6% at t0 and 75.6% at t3) were 
relatively small. The differences in rates for CUD between t0 and t3 was especially 
pronounced for CUD (2.6% prevalence at t0 versus 13.7% cumulative incidence at t3) and for 
other illicit substances (0.5% at t0 and 3.5% at t3).  
 
At t3, differences in rates between age groups were minor for use and disorders of all 
substances, except for indications of higher rates of alcohol use disorder (23.5% in the 
youngest group versus 31.8% in the oldest group) and other illicit drug use disorders, 
respectively (3.2% versus 5.1%).  
 
3.2. Cross-sectional associations between mental disorders and CU and use disorder at 
baseline  
 
To examine the cross-sectional association of a wide range of baseline mental disorders with 
CU and CUDs, Table 3 reports the prevalence of mental disorders at baseline and the 
frequency of each mental disorder by CU and CUD along with their association (odds ratio 
and 95% CI). Substance use disorders were included in the list, except for CU and CUD. At 
baseline 46.2% of all 14–17 years old met or had met during the previous life course criteria 
for at least one lifetime diagnoses listed, almost every second case met criteria for more than 
one disorder. Most frequent conditions were anxiety disorders (22.8%), substance use 
disorders (18.1%), and mood disorders (11.2%). Conduct problems were also reported 
frequently (24.3%). Controlling for gender, the cross-sectional analysis revealed that CU was 
associated with having any mental disorder (OR: 3.1; CI: 2.3–4.0), any mood disorder (OR: 
3.5; CI: 2.3–5.2), any anxiety disorder (OR: 1.7; CI: 1.2–2.3), other substance use disorders 
(OR ranged from 6.2 to 10.9) as well as with ADHD (OR: 2.1; CI: 1.0–4.1) and a middle 
(OR: 1.9; CI: 1.0–3.4) or high degree (OR: 2.2; CI: 1.3–3.8) of conduct problems in 
childhood. Among mood disorders, the odds for major depression (OR: 2.7; CI: 1.6–4.4), 
dysthymia (OR: 6.0; CI: 2.6–13.8) and hypomania/mania (OR: 4.7; CI: 2.2–10.0) are 
noteworthy. Among anxiety disorders, the odds for panic-anxiety (OR: 5.2; CI: 2.6–10.2) 
were remarkable; another association was found for separation anxiety disorder (OR: 2.3; CI: 
1.2–4.3).  
 
Associations for CUD were similar, however attenuated, probably due to lower base rates for 
CUDs. For ADHD, ODD and conduct problems, associations were not significant anymore. 
Table 3 also revealed a considerable degree of comorbidity among CUD-cases. There were 
only 10 people (18.4%) with CUD that had no co-morbid diagnosis and the majority of cases 
with CUD (59.3%) had at least one other substance use disorder. Furthermore, the number of 
comorbid diagnoses had an effect on the prevalence of CU and CUD. The probability of 
subjects with three or more comorbid diagnoses for CU was 69.6% (OR: 8.3, CI: 5.3–12.8) 
and for CUD 32.9% (OR: 12.1, CI: 5.1–28.4).  
 
3.3. Prospective associations  
 
The prospective analyses between baseline mental disorders and incident CU and CUD, 
respectively (Table 4) confirmed by and large the relationship observed in the cross-sectional 
analysis, with few exceptions. Having any disorder at baseline was associated with increased 
rates of CU (OR: 2.1; CI: 1.6–2.7) and CUD (OR: 2.4; CI: 1.6–3.5). Having comorbid 
disorders was significantly associated with increased rates of CU and CUD; associations were 
most distinct for having three or more comorbid disorders.  
 
Any substance use disorder, any mood disorder and any anxiety disorder were associated with 
CU. Among mood disorders, major depression (OR/CU: 1.9; OR/CUD: 2.5) and hypomania/ 
mania (OR/CU: 2.5; OR/CUD: 2.7) were associated with incident CU and CUD. The OR for 
dysthymia (OR/CU: 4.0) and CUD was attenuated due to low base rates and was not 
significant. Among anxiety disorders, only panic-anxiety was associated with CU (OR: 3.5; 
CI: 1.6–7.3), while for CUD significant associations were found for specific phobias (OR: 
1.8; CI: 1.1–2.9) and for GAD(OR: 3.9; CI: 1.1–13.7). For externalizing disorders a high 
degree of conduct problems was a significant predictor for CU (OR: 2.3, CI: 1.2–4.2); it is 
noteworthy, though, that for CUD none of the comparisons was significant.  
 
3.4. Age of onset characteristics for use and dependence  
 
To describe the age of onset characteristics of CU and CUD by prior history of major 
depression, bipolar disorder, as well as panic-anxiety, conduct problems and ADHD, a series 
of Cox proportional hazard analyses were run, to describe and confirm in greater detail these 
associations controlling for age and gender, taking subjects without the respective diagnoses 
as a reference. In agreement with the previous analyses, prior history of panic-anxiety 
predicted CU (p < .000) incidence. A history of major depression predicted subsequent CU 
onset (p = .006) and CUD (p = .003). For a history of conduct problems, only a higher level of 
conduct problems (three or more symptoms reported) predicted CU (p = .001), for CUD cox-
proportional hazard assumptions were not met. A history of ADHD predicted CU (p = .031), 
but not CUD. Prior history of bipolar disorder predicted the increased onset of CUD (p = 
.020), but not of CU.  
 
3.5. Effects of panic anxiety, bipolar and depressive symptoms controlling for externalizing 
disorders, age, and gender  
 
A series of multiple logistic regressions were run to test, whether the significant effects for 
specific mental disorders (depressive, bipolar and panic-anxiety) in the prospective model for 
cannabis use and disorders remain significant after controlling for the presence of 
externalizing disorders as well as age and gender effects. After controlling for externalizing 
disorders (conduct disorder, ODD and ADHD), age, and gender, the associations between 
major depression/dysthymia and CU (OR: 2.2; CI: 1.3–3.7), between hypomania/mania and 
CU (OR: 2.4; CI: 1.0–5.4) and between panic-anxiety and CU (OR: 3.1; CI: 1.4–6.8) 
remained significant. For CUD, the associations between major depression/dysthymia and 
CUD (OR: 2.4; CI: 1.3–4.5) as well as between hypomania/mania and CUD (OR: 2.7; CI: 
1.1–6.3) were significant, while the associations with panic-anxiety was attenuated and not 
significant anymore.  
 
4. Discussion  
 
The first purpose of this paper was to inform about the cumulative incidence of substance use 
and substance use disorder with an emphasis on cannabis use and cannabis use disorders in 
adolescents, aged 14–17 at baseline of the EDSP study over a period of 10 years. In 
agreement with previous publications (Holly and Wittchen, 1998; Lieb et al., 1998; Nelson 
and Wittchen, 1998; Perkonigg et al., 1998, 1999; von Sydow et al., 2001, 2002a,b; 
Zimmermann et al., 2003, 2005) the 10 years data highlight very high rates of use and abuse 
for all types of substances considered as well as the differential temporal dynamic of various 
substances. Virtually all subjects have been exposed to alcohol at some time during their life 
and almost two-thirds to nicotine. Exposure rates to cannabis were particularly high with 
more than 50% of the sample having at least tried cannabis in their lifetime. With regard to 
the temporal order of use the results indicate that first use of alcohol and nicotine occurs quite 
early in this sample. By the age of 13 for alcohol, and 14 for nicotine, the majority of all 
adolescents had used licit drugs at least once. In the majority of subjects, regular use occurred 
only slightly later (1.3 years; not reported in this paper, see Perkonigg et al., 2006).  
 
Concerning cumulative incidence of CU and CUD as the most frequent illicit drug of abuse, 
several things are notable: at baseline, the measures for CU for the youngest cohort (aged 14) 
were lower than for the three older cohorts. This may lead to the conclusion that use of 
cannabis starts at about age 15. Age of onset analysis revealed, that CU even started before 
age 15 for a significant proportion of individuals.  
 
While there is a strong increase in rates for use of cannabis between baseline and the final 
follow-up examination, the same difference is not found for nicotine and alcohol. This may 
lead to the conclusion, that the first use of cannabis takes place later in adolescence, while 
first use of legal substances like alcohol and nicotine takes place earlier. The result may be 
due to relatively liberal attitudes toward use of nicotine and alcohol (legal age of use of 
nicotine and alcohol is 16 years; very little restrictive legal regulations and few enforcement) 
in Germany. It might be of interest to examine whether this age of onset pattern is different in 
other populations with more restrictive policies.  
 
At baseline, the measures for CU for age cohorts 15, 16, and 17 ranged from 20.8% to 29.2%. 
At the final follow-up measures for all age cohorts ranged from 51.1% to 54.5%. Thus, 
numbers of first use may increase substantially between age 18 and 23. For CUD, rates for all 
age groups increase from baseline to final follow-up. While rates for alcohol 
abuse/dependence and nicotine dependence also increase, the differences between baseline 
and final follow-up is clearly more pronounced for CUD (2.6% at baseline; 13.7% at final 
follow-up). Overall, this might indicate, that first incidence of CUD tends to occur later than 
nicotine dependence and alcohol abuse/dependence. Yet, the difference between cannabis and 
alcohol resp. nicotine concerning the differences between baseline and final follow-up is not 
as distinct for CUD as for CU. At baseline, the measures for CUD for age cohorts 15, 16, and 
17 ranged from 3.2% to 3.9%; at final follow-up measures for all age cohorts ranged from 
11.5% to 16.5%. Thus, numbers of CUD may increase between age 18 and 23. For the two 
older age cohorts, increase of CUD cumulative incidence rates between baseline and final 
follow-up was not as large as for the two younger cohorts, possibly indicating the existence of 
a cohort effect that does not appear at baseline.  
 
Onset for first CU occurred on average around the age of 15, slightly before first use of other 
illicit drugs. Among substance use disorders nicotine and alcohol were the most prevalent 
with onset for abuse and dependence almost always occurring before the age of 18. The 
findings of high prevalence and high rates of concomitant substance use are by and large 
consistent with previous literature, although the early onset characteristics are remarkable and 
have important prevention and public health implications (Hawkins et al., 1992; Wittchen, 
2004). In short, one of the major public health goals for Germany should be a difference of 
age of onset of substance use, as this indicator has often been linked to problematic 
consequences and considerable costs (specifically for tobacco: Vega and Gil, 2005; other 
drugs: Hawkins et al., 1992; general considerations: Stockwell et al., 2005), even if these 
problematic consequences are reported from observations of US samples.  
 
The second goal of this paper was to describe more comprehensively than previous studies the 
association of CU and CUD with a wider range of mental disorders. Beyond the well 
established associations with externalizing disorders as well as preceding other substance use 
disorders (e.g. effects of nicotine or alcohol dependence on CU and disorders) that were 
largely confirmed in the present analyses, our findings reveal:  
 
(a) Cross-sectional associations, and weaker, but still meaningful prospective associations 
with depressive, bipolar and some anxiety disorders.  
 
(b) Most consistent associations were found for all mood disorders, including bipolar 
disorders (hypomania and mania), that also predicted increased rates for CU and CUD in the 
prospective model (except dysthymia, that did not predict CUD).  
 
(c) Among anxiety disorders, associations with specific disorders were variable. Relatively 
consistently, panic-anxiety was associated with CU and CUD and predicted CU in the 
prospective model. History of separation anxiety disorder was associated with CU and CUD, 
but not significant as a predictor. In the prospective model, GAD and specific phobias were 
associated with CUD, but not with CU. GAD and specific phobias were not associated with 
CU/CUD in the cross-sectional analysis. These findings seem to be consistent with the 
observation, that in the first decades of life, anxiety disorders have a relatively low stability 
(Wittchen et al., 2000).  
 
(d) The prospective associations for mood and anxiety disorders with CU and CUD seem to 
be similar, suggesting that the role of previous mental disorders might not be that different in 
initiating first use, developing regular use and developing dependence. Yet, notable 
exceptions might be dysthymia, panic-anxiety, and conduct problems, that predict only CU.  
 
(e) Using Cox proportional hazard modelling, taking into account mental disorders throughout 
the complete follow-up period, revealed a significant relationship with panic-anxiety for CU, 
with bipolar disorders for CUD and with major depression for CU and CUD. A history of 
ADHD as well as the highest degree of conduct problems predicted CU, but not CUD.  
 
(f) After controlling for externalizing disorders (ADHD, ODD, CD), depressive disorders, and 
hypomania/mania predicted CU as well as CUD while panic-anxiety predicted only CU.  
 
(g) No significant associations of mental disorders with CU and CUD were found for PTSD. 
It should be noted, that only few cases met criteria for PTSD.  
 
(h) Among externalizing disorders no consistent findings were found for ODD and ADHD as 
predictors for CU and CUD.  
 
To summarize, for associations and prospective associations with CU/CUD, overall, no 
homogeneous pattern could be found for the role of internalizing disorders examined in this 
paper at least with regard to the prediction of CU and CUD. Results reveal that mood 
disorders, both of uni- and bipolar form, play a significant predictor role for increased rates of 
CU and CUD, whereas the effects for anxiety disorders appeared to be variable. Some anxiety 
disorders may be of relevance for predicting increased rates, but were not frequent enough to 
verify an effect. The only consistent and strong effect was observed for panic-anxiety. 
However, panic-anxiety did not predict CUD and it needs to be studied further, whether this 
effect is indicative for specific anxiety disorders. It may also be that this finding corroborates 
results from other studies that have suggested panic anxiety might be a diagnostically 
unspecific risk marker for a whole range of psychopathologies (Goodwin et al., 2004), 
playing a significant role only in the initiation of use. This would be consistent with the 
observation that most of those using cannabis also use nicotine. Associations between nicotine 
and panic have already been discussed by Isensee et al. (2003).  
 
The fact, that associations with separation anxiety could be observed at baseline but not at 
final follow-up, as well as the fact, that associations with GAD and specific phobias and CUD 
were found at final follow-up but not at baseline may indicate, that specific disorders may 
influence CU and CUD at different points of time in adolescence and young adulthood. For 
GAD, it may be assumed that the influence of GAD on CUD takes place later in adolescence, 
since GAD itself tends to occur later in adolescence. For specific phobias, the results remain 
surprising because specific phobias tend to occur in childhood. Yet, subtypes of specific 
phobias tend to occur later and may have contributed to the results observed here. A further 
investigation of the associations of GAD and subtypes of specific phobias might be useful.  
 
It might also be useful to investigate why panic-anxiety and dysthymia were associated to CU 
and CUD and predicted CU but not CUD. These results may indicate, that the influence of 
these disorders on the development of CUD is of greater importance earlier in adolescence.  
 
The question of the specificity, the role of comorbid patterns and the implications of anxiety 
and depressive disorders and early childhood conditions on the risk for CU and CUD were not 
dealt with in this paper. However, it seems to be evident, that a wide range of 
psychopathological conditions, beyond externalising disorders plays a significant, but yet 
poorly understood role. The longitudinal interplay between early childhood and adolescent 
anxiety, depressive, and substance use and disorders other than cannabis (usually lumped 
together in the term comorbidity) clearly deserves future research attention. The most 
pronounced associations between mental disorders and CU and CUD were found for those 
with multiple disorders, both in predicting CU and CUD. Further analyses will focus on 
identifying potential syndrome specific effects in contrast to a joint diathesis of 
psychopathology in predicting use and the transitions to disorders.  
 
With regard to externalizing disorders our findings confirm the role of conduct disorders for 
increased rates of use, but less so for use disorders. It is also noteworthy, that for ADHD and 
ODD findings were not as consistent as for conduct problems. This indirectly confirms 
observations by Fergusson et al. (in this edition), who suggested that elevated substance rates 
among ADHD cases might be the consequence of comorbid conduct problems rather than a 
consequence of ADHD as suggested from a clinical perspective (Horner and Scheibe, 1997).  
 
The third goal of this paper was to examine whether internalizing disorders are associated 
with CU/CUD beyond the effects of externalizing disorders. The results found when 
controlling for externalizing disorders (ADHD, ODD, CD) suggest that depressive disorders 
and hypomania/mania independently predict CU and CUD while panic-anxiety independently 
predicts CU.  
 
In further analyses the developmental psychopathological perspective between early 
childhood syndromes and adolescent mood and anxiety disorders need to be examined more 
closely, focusing specifically on the co-variation of use of various substances. Before the 
onset of CUD, a large proportion experienced other mental or substance use disorder. For 
CUD, the exact proportion was 53.7%. 68.8% of the people with mental or substance use 
disorders prior to a CUD had an alcohol and 63.4% had a nicotine use disorder. For other 
illicit drug use disorders, in addition, CUD is a powerful predictor with an OR of 24.4 (CI: 
10.1–58.8). Among several explanations, one potential causal mechanism to explain this co-
variation may be that cannabinoids can induce behavioral sensitization and cross-sensitization 
to other drugs, especially opioids (Arnold, 2005; Cadoni et al., 2001; Lamarque et al., 2001). 
However, this speculation and hypothesis needs further testing.  
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